$329.16
00.00%
Pre-Market: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
United Therapeutics
UTHRNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
United Therapeutics (NASDAQ:UTHR) Stock, Analyst Ratings, Price Targets, Forecasts
United Therapeutics Corp has a consensus price target of $306.87 based on the ratings of 16 analysts. The high is $400 issued by Oppenheimer on May 2, 2024. The low is $240 issued by Goldman Sachs on May 3, 2024. The 3 most-recent analyst ratings were released by TD Cowen, Morgan Stanley, and UBS on July 11, 2024, July 11, 2024, and July 8, 2024, respectively. With an average price target of $347 between TD Cowen, Morgan Stanley, and UBS, there's an implied 5.42% upside for United Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
TD Cowen
Morgan Stanley
UBS
Wells Fargo
JP Morgan
1calculated from analyst ratings
Analyst Ratings for United Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/11/2024 | Buy Now | 6.33% | TD Cowen | Joseph Thome | $270 → $350 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | -2.48% | Morgan Stanley | Terence Flynn | $310 → $321 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | 12.41% | UBS | Ashwani Verma | $300 → $370 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | 6.33% | Wells Fargo | Tiago Fauth | $325 → $350 | Maintains | Overweight | Get Alert |
| 05/21/2024 | Buy Now | -8.86% | JP Morgan | Jessica Fye | $280 → $300 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | -27.09% | Goldman Sachs | Chris Shibutani | $218 → $240 | Maintains | Neutral | Get Alert |
| 05/02/2024 | Buy Now | -8.86% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 21.52% | Oppenheimer | Hartaj Singh | $375 → $400 | Maintains | Outperform | Get Alert |
| 03/07/2024 | Buy Now | -1.26% | Wells Fargo | Tiago Fauth | $309 → $325 | Maintains | Overweight | Get Alert |
| 02/22/2024 | Buy Now | -6.43% | Wedbush | Liana Moussatos | → $308 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | Buy Now | -8.86% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2024 | Buy Now | -34.68% | Goldman Sachs | Chris Shibutani | $213 → $215 | Upgrade | Sell → Neutral | Get Alert |
| 02/05/2024 | Buy Now | 0.26% | Leerink Partners | Roanna Ruiz | → $330 | Initiates | → Outperform | Get Alert |
| 11/02/2023 | Buy Now | -10.68% | JP Morgan | Jessica Fung | $290 → $294 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | -4.61% | Morgan Stanley | Terence Flynn | $318 → $314 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | -6.43% | Wedbush | Liana Moussatos | $307 → $308 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | -3.39% | Morgan Stanley | Terence Flynn | $316 → $318 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | -18.58% | Ladenburg Thalmann | Matthew Kaplan | $256 → $268 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -6.73% | Wedbush | Liana Moussatos | $305 → $307 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | -8.86% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2023 | Buy Now | -22.23% | Ladenburg Thalmann | Matthew Kaplan | $285 → $256 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | -14.93% | Argus Research | Jasper Hellweg | $300 → $280 | Maintains | Buy | Get Alert |
| 04/10/2023 | Buy Now | -5.82% | UBS | Ashwani Verma | $330 → $310 | Maintains | Buy | Get Alert |
| 04/10/2023 | Buy Now | -4% | Morgan Stanley | Terence Flynn | $320 → $316 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -14.93% | JP Morgan | Jessica Fung | $265 → $280 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -2.78% | Morgan Stanley | Terence Flynn | $330 → $320 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -8.86% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | → Buy | Get Alert |
| 01/11/2023 | Buy Now | -8.86% | Argus Research | Jasper Hellweg | $250 → $300 | Maintains | Buy | Get Alert |
| 12/06/2022 | Buy Now | 0.26% | Morgan Stanley | Terence Flynn | $322 → $330 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | -2.78% | UBS | Ashwani Verma | → $320 | Initiates | → Buy | Get Alert |
| 12/05/2022 | Buy Now | -30.13% | Goldman Sachs | Chris Shibutani | → $230 | Initiates | → Sell | Get Alert |
| 11/03/2022 | Buy Now | -19.49% | JP Morgan | Jessica Fye | $240 → $265 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | -2.18% | Morgan Stanley | Terence Flynn | $288 → $322 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 13.93% | Oppenheimer | Hartaj Singh | $325 → $375 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | -8.86% | HC Wainwright & Co. | Andrew Fein | $255 → $300 | Maintains | Buy | Get Alert |
| 10/11/2022 | Buy Now | -12.5% | Morgan Stanley | Terence Flynn | → $288 | Initiates | → Overweight | Get Alert |
| 05/24/2022 | Buy Now | -27.69% | JP Morgan | Jessica Fye | $225 → $238 | Maintains | Overweight | Get Alert |
| 05/24/2022 | Buy Now | -25.57% | Jefferies | Eun Yang | $223 → $245 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | -20.1% | Wedbush | Liana Moussatos | $236 → $263 | Maintains | Outperform | Get Alert |
| 05/24/2022 | Buy Now | -24.96% | Credit Suisse | Tiago Fauth | $219 → $247 | Maintains | Outperform | Get Alert |
| 05/24/2022 | Buy Now | -22.53% | HC Wainwright & Co. | Andrew Fein | $248 → $255 | Maintains | Buy | Get Alert |
| 04/19/2022 | Buy Now | -32.25% | JP Morgan | Jessica Fye | $230 → $223 | Maintains | Overweight | Get Alert |
| 02/28/2022 | Buy Now | -28.3% | Wedbush | Liana Moussatos | $276 → $236 | Maintains | Outperform | Get Alert |
| 02/25/2022 | Buy Now | -38.33% | Ladenburg Thalmann | Matthew Kaplan | $231 → $203 | Maintains | Buy | Get Alert |
| 02/11/2022 | Buy Now | — | BTIG | Julian Harrison | — | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for United Therapeutics (UTHR) stock?
The latest price target for United Therapeutics (NASDAQ:UTHR) was reported by TD Cowen on July 11, 2024. The analyst firm set a price target for $350.00 expecting UTHR to rise to within 12 months (a possible 6.33% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for United Therapeutics (UTHR)?
The latest analyst rating for United Therapeutics (NASDAQ:UTHR) was provided by TD Cowen, and United Therapeutics maintained their buy rating.
When was the last upgrade for United Therapeutics (UTHR)?
The last upgrade for United Therapeutics Corp happened on February 12, 2024 when Goldman Sachs raised their price target to $215. Goldman Sachs previously had a sell for United Therapeutics Corp.
When was the last downgrade for United Therapeutics (UTHR)?
The last downgrade for United Therapeutics Corp happened on July 11, 2024 when Morgan Stanley changed their price target from $310 to $321 for United Therapeutics Corp.
When is the next analyst rating going to be posted or updated for United Therapeutics (UTHR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on July 11, 2024 so you should expect the next rating to be made available sometime around July 11, 2025.
Is the Analyst Rating United Therapeutics (UTHR) correct?
While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a maintained with a price target of $270.00 to $350.00. The current price United Therapeutics (UTHR) is trading at is $329.16, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.